Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + SOX for EBV-associated Gastric Cancer
NCT05970627Phase 2Not yet recruiting
- Start
- Jul 2023
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in gastric adenocarcinoma, esophagogastric junction adenocarcinoma (GEJA). Planned start Jul 2023; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT05970627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05970627.